|Home | About | Journals | Submit | Contact Us | Français|
Nine families with autosomal dominant Alzheimer’s disease (AD), all of whom had the Ala431Glu substitution in the PSEN1 gene and came from Jalisco State in Mexico, have been previously reported. As they shared highly polymorphic flanking dinucleotide marker alleles, this strongly suggests that this mutation arose from a common founder. In the current letter, we expand this observation by describing an additional 15 independent families with the Ala431Glu substitution in the PSEN1 gene and conclude that this mutation is not an uncommon cause of early-onset autosomal dominant AD in persons of Mexican origin.
We read with interest the article by Yescas et al.  reporting nine families from Jalisco State in Mexico with early-onset autosomal dominant Alzheimer’s Disease (AD), all of whom harbored the Ala431Glu substitution in the PSEN1 gene. The identity of polymorphic dinucleotide polymorphisms flanking this gene in all mutation carriers that was absent in most non-carriers strongly suggests the descent of these persons from a common founder. In the course of our clinical and research activities in Mexico and the U.S., we have identified an additional 20 patients from 15 families with similar clinical presentations who also carry the Ala431Glu mutation and, therefore, extend the finding of a founder effect.
The 15 families were identified in Guadalajara (n=2), Chicago (n=1), and Southern California (n=12). Fourteen families were of Mexican mestizo descent and nine of these could trace the illness in their family to ancestors from Jalisco State. The remaining proband, originally from Arizona, appeared as, and identified herself as, a non-Hispanic Caucasian. Her sister, however, stated that the side of the family through whom the illness was inherited originated in Mexico though the specific location was unknown. None of the 15 families was known to be related to each other nor to any of the families evaluated by Yesca et al. in Mexico. Cognitive  and affective  changes occurring in the preclinical stage of the illness have previously been reported in at-risk members of a subset of these families and the neuropathologic findings from family N (Table 1) have been presented in abstract form .
Using techniques similar to those employed by Yesca et al. , 10 of the 20 mutation carriers, 19 related persons “at risk”, and 56 Mexican and Mexican-American controls with no history of dementia were genotyped for the polymorphic dinucleotide repeats (CA and GT) flanking the PSEN1 gene. All the samples that had the Ala431Glu mutation shared the same dinucleotide repeat alleles, (CA)19 and (GT)15. Analyses of the families showed that the Ala431Glu mutation, (CA)19, and (GT)15 always segregated together. None of the seven non-mutation carriers from the families had these alleles and only one of the 56 normal controls had the (CA)19 allele and another had the (GT)15 allele. None of the controls had both (CA)19 and (GT)15 alleles.
The age of disease onset in these families was similar to that reported by Yescas et al. (mean age of 39.5 years with the range in our sample of 33 to 44; see Table 1). All 20 affected persons presented with cognitive changes, particularly involving memory . One patient had significant depression at presentation (case M1) , one presented with predominant personality changes (case F1), and one patient’s early cognitive deficits included a substantial aphasia (case D1). In contrast to only one of nine patients having spastic paraparesis in the report by Yesca et al., nine of our 20 probands had significant spastic paraparesis within 5 years of symptom onset. Of note, all affected persons examined at a moderately advanced stage of the illness demonstrated some degree of pyramidal rigidity in all limbs and, thus, the presence of such spasticity appears to be a matter of degree rather than simply being present or absent. A pathological diagnosis of A.D. was proven on autopsy in members of five of these families .
Our independent finding of 15 additional families with autosomal dominant AD associated with the Ala431Glu substitution in PSEN1, all of those in whom the flanking CA and GT repeats were tested having shared alleles, and the fact that nine of these families could trace their roots to Jalisco confirm the findings of Yescas et al.  regarding a likely founder effect. Furthermore, we extend their observations by showing a higher prevalence of spastic paraparesis and describe an apparently non-Hispanic Caucasian with this mutation. This mutation is, therefore, not an infrequent cause of early-onset autosomal dominant AD in persons of Mexican descent in the U.S., most likely due to migration patterns.
This study was supported by Alzheimer’s Association New Investigator Research Grant 01-2797, PHS K08 AG-22228, California DHS #04-35522, and the Shirley and Jack Goldberg Trust. Further support for this study came from Alzheimer’s Disease Research Center Grants AG-16570, AG-10133, AG-16573, AG-21886, and PHS R01 AG-21055 from the National Institute on Aging, an Alzheimer’s Disease Research Center of California grant, and the Sidell Kagan Foundation.
Jill Murrell, Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202-5126, USA, Tel.: +1-317-2741757.
Bernardino Ghetti, Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202-5126, USA, Tel.: +1-317-2741757.
Elizabeth Cochran, Departments of Pathology and Neurological Sciences, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL, USA.
Miguel Angel Macias-Islas, Neurosciences Department, CUCS, University of Guadalajara, Beethoven 5216-1, La Estancia, Zapopan, Jalisco, Mexico C.P. 45030, Tel.: +52-33-36683000.
Luis Medina, UCLA Department of Neurology, Alzheimer’s Disease, Research Center, 710 Westwood Plaza, Suite 2-238, Los Angeles, CA 90095-1769, USA, Tel.: +1-310-2062687, Fax: +1-310-2065287.
Arousiak Varpetian, Department of Neurology, Keck School of Medicine, University of Southern California, Rancho Los Amigos, National Rehabilitation, 7601 Imperial Hwy, Downey, CA 90242-3456, USA, Tel.: +1-562-4016073.
Jeffrey L. Cummings, UCLA Department of Neurology, Alzheimer’s Disease, Research Center, 710 Westwood Plaza, Suite 2-238, Los Angeles, CA 90095-1769, USA, Tel.: +1-310-2062687, Fax: +1-310-2065287. Psychiatry and Biobehavioral Science, University of California, C8-827 NPI, 175919, Los Angeles, CA 90095, USA, Tel.: +1-310-8258249.
Mario F. Mendez, UCLA Department of Neurology, Alzheimer’s Disease, Research Center, 710 Westwood Plaza, Suite 2-238, Los Angeles, CA 90095-1769, USA, Tel.: +1-310-2062687, Fax: +1-310-2065287.
Claudia Kawas, Departments of Neurology, Neurobiology and Behavior, University of California, Irvine, Gillespie Neuroscience Research Facility, RM 1121, Irvine, CA 92697-4540, USA, Tel.: +1-949-8242323.
Helena Chui, Department of Neurology, Keck School of Medicine, University of Southern California, Rancho Los Amigos, National Rehabilitation, 7601 Imperial Hwy, Downey, CA 90242-3456, USA, Tel.: +1-562-4016073.
John M. Ringman, UCLA Department of Neurology, Alzheimer’s Disease, Research Center, 710 Westwood Plaza, Suite 2-238, Los Angeles, CA 90095-1769, USA, Email: ude.alcu.tendem@namgnirj Tel.: +1-310-2062687, Fax: +1-310-2065287.